TrialThe journal of prevention of Alzheimer's disease2025

A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease.

David Greeley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.